On 23 September, the Swiss-based biopharmaceutical company AC Immune announced that its partner Genentech, a member of the Roche group, has reported top line results from a Phase II clinical trial of semorinemab, an anti-tau monoclonal antibody, in early Alzheimer’s disease (AD). Unfortunately the results show that the study did not meet its primary efficacy endpoint.